262 related articles for article (PubMed ID: 35553629)
1. Seroconversion following COVID-19 vaccination: can we optimize protective response in CD20-treated individuals?
Baker D; MacDougall A; Kang AS; Schmierer K; Giovannoni G; Dobson R
Clin Exp Immunol; 2022 May; 207(3):263-271. PubMed ID: 35553629
[TBL] [Abstract][Full Text] [Related]
2. A retrospective evaluation of seroconversion after COVID-19 during the early Omicron wave in fully vaccinated multiple sclerosis patients receiving anti-CD20 therapies.
Stoll S; Desai S; Levit E
Mult Scler Relat Disord; 2023 Mar; 71():104574. PubMed ID: 36827874
[TBL] [Abstract][Full Text] [Related]
3. Strong T-cell activation in response to COVID-19 vaccination in multiple sclerosis patients receiving B-cell depleting therapies.
Alfonso-Dunn R; Lin J; Kirschner V; Lei J; Feuer G; Malin M; Liu J; Roche M; Sadiq SA
Front Immunol; 2022; 13():926318. PubMed ID: 35990701
[TBL] [Abstract][Full Text] [Related]
4. Three to four mRNA COVID-19 vaccines in multiple sclerosis patients on immunosuppressive drugs: Seroconversion and variant neutralization.
Louapre C; Belin L; Marot S; Hippolyte A; Januel E; Ibrahim M; Jeantin L; Zafilaza K; Malet I; Charbonnier-Beaupel F; Rosenzwajg M; Soulié C; Marcelin AG; Pourcher V
Eur J Neurol; 2023 Sep; 30(9):2781-2792. PubMed ID: 37310391
[TBL] [Abstract][Full Text] [Related]
5. B-cell repopulation dynamics and drug pharmacokinetics impact SARS-CoV-2 vaccine efficacy in anti-CD20-treated multiple sclerosis patients.
Asplund Högelin K; Ruffin N; Pin E; Hober S; Nilsson P; Starvaggi Cucuzza C; Khademi M; Olsson T; Piehl F; Al Nimer F
Eur J Neurol; 2022 Nov; 29(11):3317-3328. PubMed ID: 35808856
[TBL] [Abstract][Full Text] [Related]
6. COVID-19 vaccine-readiness for anti-CD20-depleting therapy in autoimmune diseases.
Baker D; Roberts CAK; Pryce G; Kang AS; Marta M; Reyes S; Schmierer K; Giovannoni G; Amor S
Clin Exp Immunol; 2020 Nov; 202(2):149-161. PubMed ID: 32671831
[TBL] [Abstract][Full Text] [Related]
7. Humoral response to COVID-19 vaccination in MS patients on disease modifying therapy: Immune profiles and clinical outcomes.
Holroyd KB; Healy BC; Conway S; Houtchens M; Bakshi R; Bhattacharyya S; Bose G; Galetta K; Kaplan T; Severson C; Singhal T; Stazzone L; Zurawski J; Polgar-Turcsanyi M; Saxena S; Paul A; Glanz BI; Weiner HL; Chitnis T
Mult Scler Relat Disord; 2022 Nov; 67():104079. PubMed ID: 35952457
[TBL] [Abstract][Full Text] [Related]
8. COVID-19 Vaccine Response in People with Multiple Sclerosis.
Tallantyre EC; Vickaryous N; Anderson V; Asardag AN; Baker D; Bestwick J; Bramhall K; Chance R; Evangelou N; George K; Giovannoni G; Godkin A; Grant L; Harding KE; Hibbert A; Ingram G; Jones M; Kang AS; Loveless S; Moat SJ; Robertson NP; Schmierer K; Scurr MJ; Shah SN; Simmons J; Upcott M; Willis M; Jolles S; Dobson R
Ann Neurol; 2022 Jan; 91(1):89-100. PubMed ID: 34687063
[TBL] [Abstract][Full Text] [Related]
9. Recall response to COVID-19 antigen is preserved in people with multiple sclerosis on anti-CD20 medications - A pilot study.
Moser T; Otto F; O'Sullivan C; Hitzl W; Pilz G; Harrer A; Trinka E; Wipfler P
Mult Scler Relat Disord; 2022 Mar; 59():103560. PubMed ID: 35093840
[TBL] [Abstract][Full Text] [Related]
10. Longitudinal COVID-19 immune trajectories in patients with neurological autoimmunity on anti-CD20 therapy.
Bazzi SA; Maguire C; Holay N; Geltman J; Hurley K; DiPasquale C; Abigania M; Olson E; Ehrlich LIR; Triplett TA; Melamed E
Mult Scler Relat Disord; 2022 Dec; 68():104195. PubMed ID: 36223705
[TBL] [Abstract][Full Text] [Related]
11. Immunity following SARS-CoV-2 vaccination in autoimmune neurological disorders treated with rituximab or ocrelizumab.
Nytrova P; Stastna D; Tesar A; Menkyova I; Posova H; Koprivova H; Mikulova V; Hrdy J; Smela G; Horakova D; Rysankova I; Doleckova K; Tyblova M
Front Immunol; 2023; 14():1149629. PubMed ID: 37398654
[TBL] [Abstract][Full Text] [Related]
12. Immune response to SARS-CoV-2 mRNA vaccination in multiple sclerosis patients after rituximab treatment interruption.
Gröning R; Dernstedt A; Ahlm C; Normark J; Sundström P; Forsell MNE
Front Immunol; 2023; 14():1219560. PubMed ID: 37575257
[TBL] [Abstract][Full Text] [Related]
13. Humoral and T-cell responses to SARS-CoV-2 vaccination in multiple sclerosis patients treated with ocrelizumab.
Katz JD; Bouley AJ; Jungquist RM; Douglas EA; O'Shea IL; Lathi ES
Mult Scler Relat Disord; 2022 Jan; 57():103382. PubMed ID: 35158475
[TBL] [Abstract][Full Text] [Related]
14. Longitudinal Postvaccine SARS-CoV-2 Immunoglobulin G Titers, Memory B-Cell Responses, and Risk of COVID-19 in Multiple Sclerosis Over 1 Year.
Disanto G; Galante A; Cantu' M; Sacco R; Mele F; Eisler JJ; Keller F; Bernasconi E; Sallusto F; Zecca C; Gobbi C
Neurol Neuroimmunol Neuroinflamm; 2023 Jan; 10(1):. PubMed ID: 36396447
[TBL] [Abstract][Full Text] [Related]
15. CD19 B cell repopulation after ocrelizumab, alemtuzumab and cladribine: Implications for SARS-CoV-2 vaccinations in multiple sclerosis.
Baker D; MacDougall A; Kang AS; Schmierer K; Giovannoni G; Dobson R
Mult Scler Relat Disord; 2022 Jan; 57():103448. PubMed ID: 34902760
[TBL] [Abstract][Full Text] [Related]
16. Response to COVID-19 booster vaccinations in seronegative people with multiple sclerosis.
Tallantyre EC; Scurr MJ; Vickaryous N; Richards A; Anderson V; Baker D; Chance R; Evangelou N; George K; Giovannoni G; Harding KE; Hibbert A; Ingram G; Jolles S; Jones M; Kang AS; Loveless S; Moat SJ; Robertson NP; Rios F; Schmierer K; Willis M; Godkin A; Dobson R
Mult Scler Relat Disord; 2022 Aug; 64():103937. PubMed ID: 35700625
[TBL] [Abstract][Full Text] [Related]
17. Comparing humoral immune response to SARS-CoV2 vaccines in people with multiple sclerosis and healthy controls: An Austrian prospective multicenter cohort study.
Bsteh G; Hegen H; Traxler G; Krajnc N; Leutmezer F; Di Pauli F; Kornek B; Rommer P; Zulehner G; Dürauer S; Bauer A; Kratzwald S; Klotz S; Winklehner M; Deisenhammer F; Guger M; Höftberger R; Berger T
Eur J Neurol; 2022 May; 29(5):1538-1544. PubMed ID: 35102646
[TBL] [Abstract][Full Text] [Related]
18. Diminished seroconversion following a single SARS-COV-2 vaccine in ocrelizumab-treated relapsing-remitting multiple sclerosis patients.
Georgieva ZG; Dӧffinger R; Kumararatne D; Coles AJ; McCarthy C
Mult Scler; 2022 Jun; 28(7):1126-1130. PubMed ID: 34595965
[TBL] [Abstract][Full Text] [Related]
19. Vaccine-based clinical protection against SARS-CoV-2 infection and the humoral immune response: A 1-year follow-up study of patients with multiple sclerosis receiving ocrelizumab.
Räuber S; Willison A; Korsen M; Kölsche T; Golombeck KS; Plaack B; Schüller J; Huntemann N; Rolfes L; Schroeter CB; Nelke C; Regner-Nelke L; Förster M; Ringelstein M; Barnett MH; Hartung HP; Aktas O; Albrecht P; Ruck T; Melzer N; Meuth SG; Kremer D
Front Immunol; 2022; 13():1037214. PubMed ID: 36618356
[TBL] [Abstract][Full Text] [Related]
20. Humoral and cellular responses to repeated COVID-19 exposure in multiple sclerosis patients receiving B-cell depleting therapies: a single-center, one-year, prospective study.
Alfonso-Dunn R; Lin J; Lei J; Liu J; Roche M; De Oliveira A; Raisingani A; Kumar A; Kirschner V; Feuer G; Malin M; Sadiq SA
Front Immunol; 2023; 14():1194671. PubMed ID: 37449202
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
